Patient: Page 2


  • neck pain stock
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Tonix closes in on the first new fibromyalgia drug in more than a decade

    In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

    By Kelly Bilodeau • Jan. 29, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By Jan. 26, 2024
  • test tube gene Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaVoice staff
  • 2024 outlook
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The biggest questions hanging over pharma in 2024

    Key trends on the horizon in the life sciences this year.

    By Jan. 25, 2024
  • King Charles III
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

    The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

    By Jan. 25, 2024
  • MRI machine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Breast cancer tops list of most studied diseases

    The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

    By Kelly Bilodeau • Jan. 24, 2024
  • hand syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Controversial challenge trials offer unparalleled innovation — with ethical bumps

    Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.

    By Kelly Bilodeau • Jan. 22, 2024
  • Chris Arendt
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip

    Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

    Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

    By Jan. 19, 2024
  • Covid doctor
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    An enduring COVID mystery: Why some do fine and others die

    The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

    By Alexandra Pecci • Jan. 17, 2024
  • gut microbiome
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma takes a gut check of microbiome drugs

    On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

    By Kelly Bilodeau • Jan. 16, 2024
  • San Francisco
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    Pharma execs sound off on trends and policies they’re tracking in 2024

    From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

    By Jan. 12, 2024
  • 2024 Crystal Ball Trials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion // Year in Preview

    PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials

    As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.

    By Jan. 11, 2024
  • Black patient mental health
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    How J&J is tackling a ‘secondary pandemic’ in the Black community

    J&J is leading a grassroots effort to improve mental health access and care.

    By Alexandra Pecci • Jan. 8, 2024
  • DNA vile
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Regulatory twists and turns are coming for biopharma in 2024

    New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

    By Kelly Bilodeau • Jan. 8, 2024
  • Alzheimer's patient
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Alzheimer’s research is hot, but successful patient recruitment will determine its future

    Key strategies for bringing more patients into the clinical trial fold.

    By Kelly Bilodeau • Jan. 4, 2024
  • pill explosion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    10 of our most read articles in 2023

    A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

    By Dec. 22, 2023
  • A gloved hand holds a DNA microscope slide.
    Image attribution tooltip

    Massachusetts General Hospital

    Image attribution tooltip
    Deep Dive

    As ALS research booms, one treatment center finds itself in the spotlight

    The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.

    By Jacob Bell • Dec. 22, 2023
  • blockbuster drugs
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What are pharma’s next blockbusters?

    In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

    By Kelly Bilodeau • Dec. 20, 2023
  • dollar sign
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 noteworthy pharma AI investments in 2023

    The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.

    By Alexandra Pecci • Dec. 19, 2023
  • Babson testing device
    Image attribution tooltip
    Permission granted by Babson Diagnostics
    Image attribution tooltip

    Babson gets one step closer to delivering on Theranos-like blood testing

    A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.

    By Kelly Bilodeau • Dec. 18, 2023
  • drug prices
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Study suggests PBMs are gaming pharmacy system to overcharge for drugs

    Markups for generics can be as high as 7,000%, the researchers said.

    By Alexandra Pecci • Dec. 15, 2023
  • Quita Highsmith header
    Image attribution tooltip
    Permission granted by Quita Highsmith
    Image attribution tooltip
    Q&A

    The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them

    Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.

    By Dec. 14, 2023
  • COVID pandemic
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    What’s being done to prepare for the next pandemic?

    Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.

    By Kelly Bilodeau • Dec. 13, 2023
  • Dr. Julie Gerberding headshot
    Image attribution tooltip
    Permission granted by FNIH
    Image attribution tooltip
    Q&A

    A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

    Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

    By Dec. 13, 2023
  • Professional photo of Adam Lenkowsky
    Image attribution tooltip
    Permission granted by Adam Lenkowsky
    Image attribution tooltip
    Q&A

    Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

    Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

    By Dec. 12, 2023
  • Chemotherapy cancer
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Oncology drugmakers seek the sweet spot between efficacy and tolerability

    The FDA is now pushing companies to find the optimal dose early in development to minimize harm.

    By Kelly Bilodeau • Dec. 11, 2023